Roche Acquires Adheron Therapeutics and Lead Asset, SDP051

Adheron Therapeutics has been acquired by Roche in a deal worth up to $580 million. The lead asset, SDP051, a humanized monoclonal antibody targeting Cadherin-11, has completed Phase 1 of clinical development. Antibody Solutions is proud to have played a key role in the discovery of the murine form of SDP051 and to have supported the development of SDP051.

Share this

Add your comment

Your email address will not be published. Required fields are marked *